Welcome to our dedicated page for Xeriant SEC filings (Ticker: XERI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Xeriant, Inc. (XERI) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current and historical documents filed with the U.S. Securities and Exchange Commission. These filings offer structured insight into Xeriant’s financial reporting, material agreements, and corporate developments related to its focus on advanced materials and transformative technologies.
Investors can review periodic reports such as Forms 10-K and 10-Q, which contain audited or reviewed financial statements, management’s discussion of results, and information about risk factors and operations. When Xeriant requires additional time to complete a quarterly report, it may file a Form 12b-25 (NT 10-Q), as it did for the quarter ended September 30, 2025, explaining the reasons for the delay and indicating the expected filing timeframe.
The filings page also includes current reports on Form 8-K, where Xeriant discloses material events and agreements. For example, a Form 8-K dated November 2025 describes a settlement agreement with Auctus Fund, LLC relating to a senior secured promissory note, including the issuance of common stock, scheduled cash payments, and mutual releases of certain claims, as well as a related leak-out agreement. Such documents help readers understand changes in the company’s capital structure and key contractual obligations.
Stock Titan enhances these filings with AI-powered summaries that highlight key terms, timelines, and implications, helping users interpret complex agreements and technical language. Real-time updates from EDGAR ensure that new XERI filings, including future 10-Ks, 10-Qs, 8-Ks, and other forms, are added promptly. Users can also reference ownership-related filings such as Form 4 when available to monitor insider share transactions. This page serves as a centralized resource for analyzing Xeriant’s regulatory history, financial reporting patterns, and disclosed material events.
Xeriant, Inc. reported quarterly results for the three months ended September 30, 2025, showing net income of $2,226,072 driven largely by a $2,743,546 gain on extinguishment of debt from a settlement of its senior secured note with Auctus Fund. Operating activities still produced a loss of $304,075 as the company continues to invest in consulting, R&D and professional fees while generating no disclosed revenue.
At September 30, 2025, Xeriant had cash of $52,136, total assets of $71,730 and a stockholders’ deficit of $5,702,498, including a working capital deficit of $5,710,579. Management states there is substantial doubt about the company’s ability to continue as a going concern and estimates existing cash would last about two months from mid-November 2025 without new funding. The company is pursuing additional capital via equity and debt while advancing its DUREVER and NEXBOARD advanced materials portfolio and maintaining an ongoing lawsuit against XTI Aircraft Company.
Xeriant, Inc. filed a Form 12b-25 (NT 10-Q) notifying a late filing for its quarterly report for the period ended September 30, 2025. The company states it cannot file within the prescribed time without unreasonable effort and expense.
Xeriant cites the need for additional time to complete the presentation of certain information in its financial statements and related notes and to compile supporting documentation. The company expects to file the Form 10-Q no later than the fifth calendar day after the prescribed due date.
Xeriant, Inc. entered into a Settlement Agreement with Auctus Fund tied to a prior senior secured promissory note. The agreement, effective retroactive to October 29, 2025, includes issuing 30,000,000 unrestricted common shares to Auctus pursuant to a February 24, 2025 conversion notice and a commitment for cash payments totaling $3,500,000.
Cash installments are scheduled as follows: $1,000,000 on or before 75 days from October 29, 2025; $1,000,000 on or before 105 days; $1,000,000 on or before 135 days; and $500,000 on or before 165 days. Auctus will suspend further conversions under the note so long as payments are made. If payments are timely, Auctus will return two warrants (each for 25,000,000 shares); Auctus retains an original warrant for 50,968,828 shares. The company will share any proceeds it receives from its legal action against XTI Aircraft Company on a preferred basis, net of legal fees capped at $250,000. The 30,000,000 shares are being issued under Section 4(a)(2) of the Securities Act. A leak-out agreement governs Auctus’s sales of received stock.
Xeriant, Inc. reports significant liquidity and capital structure issues while advancing a new product initiative. The company had a $8,708,900 working capital deficit and notes that, based on historical spending, it expects to expend available cash in approximately three months from October 2, 2025, creating substantial doubt about its ability to continue as a going concern. The filing discloses 749,053,035 outstanding common shares and extensive convertible instruments: warrants totaling roughly 111,568,828 and 118,968,828 outstanding in different series and multiple convertible notes with low conversion prices and adjustment features. The company is developing NEXBOARD, a wallboard product that requires industry certification, and appointed two senior advisors in nanomaterials. Significant financing arrangements include a note from Auctus with conversion activity and related legal dispute, plus outstanding notes with conversion at $0.01 per share.
FAQ
What is the current stock price of Xeriant (XERI)?
What is the market cap of Xeriant (XERI)?
